VCM
BCAX

Versant Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Versant Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Hold
434
– – ﹤0.01% 2148
2026
Q1 		$8.63K Buy
434
+326
+302% +$5.61K ﹤0.01% 2196
2025
Q4 		$1.82K Buy
108
+13
+14% +$222 ﹤0.01% 2460
2025
Q3 		$1.5K Hold
95
– – ﹤0.01% 2456
2025
Q2 		$883 Buy
+95
New +$1.13K ﹤0.01% 2499

Other funds holding BCAX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's BCAX Position: Q2 2026 in Review

Versant Capital Management held its Bicara Therapeutics (BCAX) position steady in Q2 2026 at 434 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2148.

Versant Capital Management first reported a position in BCAX in Q2 2025 and has held it in 5 quarters since. 5 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Versant Capital Management held 434 shares of Bicara Therapeutics worth $12.9K as of Q2 2026.
  • Versant Capital Management left its Bicara Therapeutics share count unchanged in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2148 holding.
  • Versant Capital Management first reported a position in Bicara Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 5 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.